Perfusion Medical was awarded an Air Force Phase 1 STTR from the AFWERX Program. The company’s academic partner is Virginia Commonwealth University. Perfusion Medical and VCU will be working with Air Force stakeholders working to validate the efficacy of their drug PM-208, in hemorrhagic shock with uncontrolled bleeding. Hemorrhagic shock impacts 1,000,000 military and civilian patients worldwide every year. 

As the innovation arm of the Department of the Air Force and powered by the Air Force Research Laboratory (AFRL), AFWERX brings cutting edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX teams internationally across academia, industry, and government to develop technology, expand talent and transition dual-use capabilities.